



Certificate of Analysis

www.tocris.com

Product Name: 8-Bromo-cGMP, sodium salt Catalog No.: 1089 Batch No.: 8

CAS Number: 51116-01-9 EC Number: 256-993-8

IUPAC Name: 8-Bromoguanosine cyclic 3',5'-monophosphate sodium salt

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{10}H_{10}BrN_5NaO_7P.H_2O$

Batch Molecular Weight: 464.11

Physical Appearance: White solid

Solubility: water to 100 mM

Storage: Desiccate at -20°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 99.9% purity

1H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 25.88 2.61 15.09 Found 25.63 2.77 14.81



Product Information

Print Date: Apr 5th 2017 **WWW.tocris.com**

Product Name: 8-Bromo-cGMP, sodium salt Catalog No.: 1089 Batch No.: 8

CAS Number: 51116-01-9 EC Number: 256-993-8

IUPAC Name: 8-Bromoguanosine cyclic 3',5'-monophosphate sodium salt

Description:

Membrane permeable cGMP analog that activates protein kinase G (PKG). 4.3-fold more potent than cGMP in activating PKG1 α and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro.

Physical and Chemical Properties:

Batch Molecular Formula: C₁₀H₁₀BrN₅NaO₇P.H₂O

Batch Molecular Weight: 464.11 Physical Appearance: White solid

Minimum Purity: >98%

Batch Molecular Structure:

Storage: Desiccate at -20°C

Solubility & Usage Info:

water to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Sekhar *et al* (1992) Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type 1α , compared with type 1β , cGMP-dependent protein kinase. Mol.Pharmacol. *42* 103. PMID: 1321950.

Buchan et al (1991) Modulation of agonist-induced calcium mobilisation in bovine aortic endothelial cells by phorbol myristate acetate and cyclic AMP but not cyclic GMP. Br.J.Pharmacol. **104** 361. PMID: 1665733.

Ignarro *et al* (1974) Stimulation of phagocytic release of neutral protease from human neutrophils by cholinergic amines and cyclic 3',5'-guanosine monophosphate. J.Immunol. *112* 210. PMID: 4359834.